To the full analysis
Guardant Health stock: growth
GHGuardant Health reported $982.02M in revenue for fiscal 2025, up 32.9% on the prior year, up 27.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
50.2%
per year from 2016 to 2025, per share 17%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2016 | |
|---|---|---|
| Revenue | 27.9% | 50.2% |
| Revenue per share | 21.6% | 17.0% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2016 | $25.25M | −$46.14M | −$38.48M |
| 2017 | $49.84M | −$83.22M | −$81.22M |
| 2018 | $90.64M | −$85.06M | −$92.39M |
| 2019 | $214.38M | −$75.65M | −$68.42M |
| 2020 | $286.73M | −$253.78M | −$157.99M |
| 2021 | $373.65M | −$405.67M | −$284.05M |
| 2022 | $449.54M | −$654.59M | −$386.92M |
| 2023 | $563.95M | −$479.45M | −$345.46M |
| 2024 | $739.02M | −$436.37M | −$274.94M |
| 2025 | $982.02M | −$416.28M | −$233.07M |
Revenue by segment
How Guardant Health, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Oncology$683.6M70%
- Biopharma & Data$210.1M21%
- Screening$79.7M8%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| Oncology | $683.6M | 69.6% |
| Biopharma & Data | $210.13M | 21.4% |
| Screening | $79.73M | 8.1% |
| Total revenue | $982.02M | 100% |
Revenue by region
Where Guardant Health, Inc. generates its revenue.
- United States94%
- Outside the US6%
Figures as a table
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| United States | $77.92M | $194.31M | $264.66M | $352.56M | $420.62M | $526.52M | $697.16M | $923.28M | 94% |
| Outside the US | $12.72M | $20.06M | $22.07M | $21.09M | $28.92M | $37.42M | $41.85M | $58.74M | 6% |
| Total revenue | $90.64M | $214.38M | $286.73M | $373.65M | $449.54M | $563.95M | $739.02M | $982.02M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 28 Feb 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.